Levosimendan Altan (Levosimendan)

• Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.
• Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
• Severe left‑ventricular systolic dysfunction: enhances contractility and reduces filling pressures.
• Post‑cardiac surgery low‑output syndrome: supports hemodynamics when conventional therapy is insufficient.

• Levosimendan increases cardiac contractility by binding to troponin C and sensitizing it to calcium, which enhances the force of myocardial contraction without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing after‑load, thereby improving overall cardiac output.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: often transient during infusion.
• Nausea or vomiting: gastrointestinal discomfort.
• Tachycardia: increased heart rate.
• Dizziness: related to blood pressure changes.
• Flushing: warm sensation on skin.

Serious or Rare Side Effects

• Severe hypotension: may require vasopressor support.
• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain or ECG changes.
• Pulmonary edema: worsening respiratory status.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Liver enzyme elevation: abnormal hepatic function tests.

• When administering Levosimendan, several safety considerations should be observed.
• Cardiovascular monitoring: continuously monitor blood pressure and heart rate during infusion.
• Renal impairment: adjust infusion rate or consider alternative therapy in severe renal dysfunction.
• Hepatic impairment: use with caution in patients with significant liver disease.
• Concomitant vasodilators: avoid excessive hypotension by adjusting doses.
• Electrolyte disturbances: correct potassium and magnesium abnormalities before starting therapy.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other cardiovascular agents, requiring careful management.

Major Interactions (Avoid)

• Sodium nitroprusside: additive hypotensive effect.
• Phosphodiesterase inhibitors (e.g., milrinone): risk of severe hypotension.
• Beta‑blockers: may blunt the intended inotropic response.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: monitor for excessive blood pressure drop.
• Diuretics: watch electrolyte levels and volume status.
• Calcium channel blockers: observe for bradycardia or conduction abnormalities.